2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines

Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines

The Canadian Task Force on Preventive Health Care (CTFPHC) provides independent, evidence-based clinical practice guidelines to assist primary care clinicians in delivering preventive healthcare services. Guidelines rely on the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework, categorizing recommendations as strong or conditional (weak) based on the certainty of evidence, the magnitude of net benefit versus harm, and patient values and preferences.

For the MCCQE Part I, candidates must recognize that Canadian preventive guidelines frequently differ from US guidelines (such as the USPSTF or specialty society guidelines). Canadian examination questions strictly test CTFPHC recommendations, emphasizing shared decision-making, reduction of overdiagnosis, and cost-effective population health management.

---

Breast Cancer Screening Guidelines

Breast cancer is the most common cancer among Canadian women. CTFPHC guidelines apply to average-risk women aged 40 to 74 who have no personal history of breast cancer, no known BRCA1/BRCA2 mutations, no prior chest radiation, and no first-degree relatives with premenopausal breast cancer.

CTFPHC Breast Screening Recommendations

• Women Aged 40–49 Years: Conditional recommendation against routine screening with mammography. The absolute benefit in mortality reduction is low (1 death prevented per 1,700 women screened over 10 years), while risks of false-positive results, unnecessary diagnostic biopsies, and overdiagnosis are high. Clinicians should engage in shared decision-making if a patient expresses a personal preference for screening after reviewing harms and benefits.
• Women Aged 50–69 Years: Conditional recommendation for screening with mammography every 2 to 3 years.
• Women Aged 70–74 Years: Conditional recommendation for screening with mammography every 2 to 3 years.
• Women Aged 75 Years and Older: No routine screening recommended due to lack of direct trial evidence and competing causes of mortality.
• Clinical Breast Exam (CBE) & Breast Self-Exam (BSE): Strong recommendation against performing routine CBE or advising BSE for screening average-risk women, as evidence demonstrates no reduction in breast cancer mortality and significant increases in false-positive diagnostic procedures.

---

Cervical Cancer Screening Guidelines

Cervical cancer screening aims to detect persistent high-risk Human Papillomavirus (hrHPV) infections and precancerous cervical intraepithelial neoplasia (CIN) prior to malignant transformation.

Target Population & Screening Protocol

• Women Aged <25 Years: Strong recommendation against screening. Cervical dysplasia in this age group is overwhelmingly transient and cleared spontaneously by the immune system. Screening leads to over-investigation, overtreatment (e.g., LEEP procedures), and increased risks of future cervical incompetence and preterm labor.
• Women Aged 25–69 Years: Recommended screening every 3 years with liquid-based cytology (Pap test) or primary hrHPV DNA testing every 5 years (as provinces transition to primary HPV testing).
• Women Aged ≥70 Years: Screening may be discontinued if the individual has had 3 consecutive negative Pap tests or 2 negative hrHPV tests within the preceding 10 years.
• Post-Hysterectomy: Screening is not indicated if the patient underwent a total hysterectomy for benign disease with a documented history of normal cervical cytology.

---

Colorectal Cancer (CRC) Screening Guidelines

Colorectal cancer screening targets asymptomatic, average-risk adults aged 50 to 74 years. Average risk excludes individuals with personal inflammatory bowel disease (Ulcerative Colitis, Crohn's), hereditary polyposis syndromes (FAP, Lynch syndrome), or a first-degree relative diagnosed with CRC before age 60.

Primary Screening Modalities & Intervals

1. Fecal Immunochemical Test (FIT): Preferred primary modality in most Canadian jurisdictions. Administered every 1 to 2 years. FIT specifically detects human hemoglobin, requiring only a single stool sample without dietary restrictions.
2. Guaiac Fecal Occult Blood Test (gFOBT): Acceptable alternative, administered every 1 to 2 years (requires 3 consecutive stool samples and dietary restrictions).
3. Flexible Sigmoidoscopy: Acceptable screening option every 10 years.
4. Colonoscopy: The CTFPHC conditionally recommends against using colonoscopy as a primary screening tool for average-risk individuals. Colonoscopy carries higher procedural risks (bowel perforation, hemorrhage, sedation complications) and resource demands. Primary colonoscopy is reserved for high-risk individuals or diagnostic follow-up of a positive FIT/sigmoidoscopy.
5. Adults Aged ≥75 Years: Routine screening is not recommended due to diminishing net benefit.

---

Prostate Cancer Screening Guidelines

Screening for prostate cancer using Prostate-Specific Antigen (PSA) testing remains one of the most tested topics on the MCCQE Part I due to substantial controversy surrounding overdiagnosis.

CTFPHC PSA Recommendations

• Men Aged <55 Years & Men Aged ≥70 Years: Strong recommendation against screening with PSA.
• Men Aged 55–69 Years: Conditional recommendation against routine PSA screening.
• Clinical Rationale: PSA screening leads to a minimal reduction in prostate cancer-specific mortality (1 death prevented per 1,000 men screened over 13 years) but results in high rates of false-positive testing, needle biopsy complications (infection, bleeding, pain), and overtreatment of indolent tumors causing long-term urinary incontinence and erectile dysfunction.
• Shared Decision-Making: If a male patient explicitly requests PSA testing, the physician must conduct a balanced discussion covering the high probability of false positives, biopsy risks, and potential treatment sequelae before ordering the test.

---

Lung Cancer Screening Guidelines

Lung cancer is the leading cause of cancer mortality in Canada. Screening aims to detect early-stage non-small cell lung cancer in high-risk smokers.

• Target Population: Adults aged 55 to 74 years with a ≥30 pack-year smoking history who currently smoke or quit within the past 15 years.
• Screening Modality: Low-Dose Computed Tomography (LDCT) annually for 3 consecutive years.
• Exclusions: Individuals with significant co-morbidities that severely limit life expectancy or candidate suitability for curative lung surgery.

---

Chronic Disease Screening: Hypertension, Diabetes & Osteoporosis

Exam Trap: On the MCCQE Part I, do NOT select primary screening colonoscopy for an average-risk 52-year-old patient. The correct CTFPHC answer is Fecal Immunochemical Test (FIT) every 1 to 2 years. Colonoscopy is only first-line screening for high-risk patients (e.g., first-degree relative with CRC <60 years or known Lynch syndrome).

Clinical Scenario: A 54-year-old male with no family history of cancer presents for an annual check-up and asks for a "full blood work cancer panel," specifically requesting a PSA test. What is the most appropriate management?
Answer: Engage in shared decision-making. Inform the patient that the CTFPHC conditionally recommends against routine PSA screening because the minor potential reduction in prostate cancer mortality is outweighed by high rates of false positives, biopsy risks, overdiagnosis, and treatment complications such as erectile dysfunction and incontinence. Respect his informed decision if he declines or still requests testing after counseling.